Results 111 to 120 of about 67,411 (205)

Preoperative Gemcitabine/Nab‐Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone

Annals of Gastroenterological Surgery, Volume 10, Issue 4, Page 1209-1216, July 2026.
ABSTRACT Background Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR‐PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab‐paclitaxel (GnP‐RT) compared to gemcitabine alone ...
Hirofumi Akita, Hidenori Takahashi, Yousuke Mukai, Masahiko Kubo, Shinichiro Hasegawa, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Hiroshi Wada, Kunihito Gotoh   +9 more
wiley   +1 more source

Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.

Annals of Oncology, 2019
BACKGROUND Capecitabine plus oxaliplatin (XELOX) has shown modest activity and tolerable toxicity in a phase II trial for biliary tract cancers (BTCs). Meanwhile, gemcitabine plus oxaliplatin (GEMOX) has been the reference arm in recent phase II and III ...
Seung-Tae Kim, J. Kang, J-W. Lee, Hyun Woo Lee, S. Oh, J. Jang, Myung-Ah Lee, B. Sohn, S. Yoon, Hye Jin Choi, J. Hong, M. Kim, Si-Ho Kim, Y. Park, J. Park, Ho Yeong Lim   +15 more
semanticscholar   +1 more source

Management Strategies for Disappearing Colorectal Liver Metastases After Systemic Chemotherapy: Long‐Term Outcomes and Preoperative Prediction of ‘True Complete Response’

Annals of Gastroenterological Surgery, Volume 10, Issue 4, Page 1239-1249, July 2026.
ABSTRACT Background Determining whether to resect disappearing liver metastases (DLMs) after chemotherapy for colorectal liver metastases (CRLMs) remains challenging. Methods Patients who underwent hepatectomy after systemic chemotherapy for initially unresectable CRLMs were reviewed. True complete response (CR) was defined as either resected DLMs with
Taihei Soma, Ryo Ashida, Takeshi Kawakami, Katsuhisa Ohgi, Mihoko Yamada, Shimpei Otsuka, Yoshiyasu Kato, Kentaro Yamazaki, Katsuhiko Uesaka, Teiichi Sugiura   +9 more
wiley   +1 more source

Clinical observation of capecitabine in the maintenance treatment of advanced breast cancer

Zhongguo aizheng zazhi, 2014
Background and purpose: Capecitabine, which is widely used in the first-line treatment of advanced breast cancer, was known little in the maintenance treatment of advanced breast cancer.
李剑英, 季从飞, 陈佳, 谭清和
doaj  

Photosensitive lichenoid skin reaction to capecitabine

BMC Cancer, 2017
Background Capecitabine is an oral prodrug of fluorouracil, which is a common agent used in the management of many solid tumor malignancies. Dermatologic reaction is common with various chemotherapy agents but is not commonly reported in the use of ...
Rena A. Shah, Daniel D. Bennett, Mark E. Burkard   +2 more
doaj   +1 more source

Relationship Between the Product of Pre‐Treatment Neutrophil and Monocyte Counts and Clinical Outcomes in Rectal Cancer With Suspected Lateral Lymph Node Metastasis

Annals of Gastroenterological Surgery, Volume 10, Issue 4, Page 1097-1106, July 2026.
ABSTRACT Aim A novel systemic inflammatory response marker, the neutrophil × monocyte value (NM value), has been identified as a negative predictive factor for responses to chemoradiotherapy in rectal cancer. However, the clinical implications of the NM value remain unknown.
Takayoshi Sasaki, Shinya Abe, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Yuzo Nagai, Yuzo Harada, Soichiro Ishihara   +9 more
wiley   +1 more source

Capecitabine-induced cicatricial ectropion: A case review

The Pan-American Journal of Ophthalmology
Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), offers a more targeted chemotherapeutic approach, reducing systemic side effects. However, cases of ocular side effects have been described in the literature. We report the case of a 94-year-old man
Stuti Misty Tanya, Andrea Dahoud, Ahmed Al-Amer, Bryan Arthurs, Christian El-Hadad   +4 more
doaj   +1 more source

Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer

Breast Cancer: Basic and Clinical Research, 2011
Breast Cancer is the most prevalent cancer in the world with 4.4 million survivors up to 5 years following the diagnosis. 1 In the US alone approximately forty thousand women die annually of metastatic breast cancer (MBC). Despite many effective systemic
Katherine H. Rak Tkaczuk
doaj   +1 more source

Association of the PD‐L1 CPS With the Efficacy of First‐Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer

Cancer Medicine, Volume 15, Issue 7, July 2026.
ABSTRACT Background The CheckMate 649 trial showed the superiority of first‐line nivolumab plus chemotherapy (Nivo‐CT) over chemotherapy alone for advanced gastric or gastroesophageal junction (GEJ) cancer with a programmed cell death‐ligand 1 (PD‐L1) combined positive score (CPS) ≥ 5.
Nozomu Ogura, Misa Ohnishi, Rin Inamoto, Yosuke Kito, Kengo Nagashima, Naoki Takahashi, Mitsuhiro Furuta, Hirokazu Shoji   +7 more
wiley   +1 more source

Metastatic Unfunctional Pancreatic Neuroendocrine Tumor in Lynch Syndrome

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Lynch syndrome (LS), a well‐known cancer risk syndrome, is caused by deleterious germline mutations in the mismatch repair genes. LS predispose patients to various types of cancers including colon adenocarcinoma. We discuss the case of a woman with LS who also developed a non‐functioning pancreatic neuroendocrine tumor (P‐NET) following ...
Fateme Salemi, Zahra Sadin, Atefe Barzegari, Seyed Mohammad Reza Mortazavizadeh, Massih Bahar, Motahare Amiri   +5 more
wiley   +1 more source